文献速递骨质疏松与钙磷/甲状旁腺

长期使用质子泵抑制剂与骨密度及骨质量降低的性别特异性关联

Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究从2005至2008年NHANES周期提取7478名受试者(男性3961名,女性3517名)的个体数据,评估长期使用质子泵抑制剂与骨小梁评分及骨密度的关联。多变量线性回归分析显示,长期使用PPI与男性骨小梁评分降低及腰椎、全髋、股骨颈T值降低相关,且在进一步校正骨密度后关联仍显著;女性中未观察到显著关联。

要点

  • 长期使用PPI与男性骨小梁评分降低相关(-0.039;95%CI,-0.058至-0.020;P<.001)。
  • 男性长期使用PPI与腰椎、全髋、股骨颈T值降低相关。
  • 女性中长期使用PPI与骨小梁评分或骨密度无显著关联。

核心结论

  • 长期使用PPI与男性骨小梁质量降低相关,即使在校正骨密度后仍显著;女性中未观察到关联。

研究设计与样本

  • 从2005至2008年NHANES周期提取个体数据,共纳入7478名受试者(男性3961名,女性3517名),采用多变量线性回归按性别分层分析。

主要发现

  • 男性长期使用PPI与骨小梁评分降低相关(-0.039;95%CI,-0.058至-0.020;P<.001)。
  • 男性长期使用PPI与腰椎T值降低相关(-0.27;95%CI,-0.51至-0.04;P=.023)。
  • 男性长期使用PPI与全髋T值降低相关(-0.21;95%CI,-0.41至-0.01;P=.041)。
  • 男性长期使用PPI与股骨颈T值降低相关(-0.22;95%CI,-0.44至-0.00;P=.047)。
  • 进一步校正腰椎和股骨颈骨密度后,男性长期使用PPI与骨小梁评分降低的关联仍显著(-0.026;95%CI,-0.039至-0.012;P=.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Chronic use of proton pump inhibitors (PPIs) has been associated with an increase in bone fragility. However, evidence on the effect of chronic PPI use on bone density is conflicting, and data on bone microarchitectural quality are scarce. OBJECTIVE: The primary aim of this study was to evaluate whether trabecular bone microarchitecture, assessed by trabecular bone score (TBS), is altered in chronic PPI users. The association between PPI use and bone density was also evaluated as a secondary endpoint. METHODS: We extracted individual patient data from the 2005 to 2008 cycles of the population-based National Health and Nutrition Examination Survey (NHANES), in which lumbar spine dual-energy X-ray absorptiometry scans were acquired. TBS values were calculated from dual-energy X-ray absorptiometry images using a dedicated software. Multivariable linear regression analyses stratified by sex were performed to evaluate the association of chronic PPI use with TBS and bone mineral density (BMD), adjusting for relevant confounders. RESULTS: A total of 7478 subjects were included (3961 men, 3517 women). After adjustment for relevant confounders, chronic PPI use was associated with a worse bone health profile in men, with lower TBS (-0.039; 95% CI, -0.058 to -0.020; P < .001), lumbar spine T-score (-0.27; 95% CI, -0.51 to -0.04; P = .023), total hip T-score (-0.21; 95% CI, -0.41 to -0.01; P = .041), and femoral neck T-score (-0.22; 95% CI, -0.44 to -0.00; P = .047). Notably, the association between chronic PPI use and degraded TBS remained statistically significant even after further adjustment for BMD at lumbar spine and femoral neck (-0.026; 95% CI, -0.039 to -0.012; P = .001). In contrast, no significant association was observed between chronic PPI use and either TBS or BMD in women. CONCLUSION: Chronic PPI use is associated with degraded trabecular bone quality in men, even after adjustment for BMD. No association was observed in women.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bioletto F, Pusterla A, Fraire F, et al. Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality. J Clin Endocrinol Metab. 2025. PMID: 39197024. doi:10.1210/clinem/dgae598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。